Home

Pharmacology

Read time: 3 min

Satellite symposium

Promising data in depression associated with emotional blunting or trauma

Treatment for depression should be tailored to individuals’ history and presentation....

Read time: 3 min

Satellite symposium

Optimizing early treatment central in reducing burden of resistant depression

Treatment-resistant depression is associated with a high disease burden, functional impairment,...

Read time: 2 min

Satellite symposium

Improving positive and negative symptoms with dopamine D2 partial agonists

Dopamine D2 partial agonists can ameliorate both positive and negative symptoms of schizophrenia...

Read time: 2 min

Congress highlights

What causes migraine and how can it be prevented?

Calcitonin gene-related peptide (CGRP) plays a causative role in migraine, said Antoinette Maassen...

Read time: 2 min

Congress highlights

Unmet needs in the acute treatment of migraine

What are the acute treatment options for migraine if current medications are not effective, are...

Parkinson's Disease

Read time: 2 min

Congress highlights

2020 Update on strategies to improve motor symptoms

In 2020, when should a person diagnosed with Parkinson’s disease start treatment? Which...

CGRP – new perspectives in headache management

Three new takes on the potential for calcitonin gene-related proteins were presented at this year...

CGRP – new perspectives in headache management

Read time: 2 min

Congress highlights

Preclinical pearls offer insights into migraine sex differences and sensory thresholds

Speaking at #MTIS2020, Professor Frank Porreca, University of Arizona, USA, identified recent...

Read time: 3 min

Congress highlights

Addressing the gender bias in mental health research

There are significant differences between women and men in disease presentation, underlying...

Read time: 2 min

Congress highlights

Forty thousand users and counting: science-based nomenclature takes off

Classifying drugs by mechanism of action rather than by indication should clarify the rationale for...

Read time: 2 min

Congress highlights

Expert guidance on management of schizophrenia for a better quality of life and independence

Individualized patient management is key to achieving better lifetime quality of life and...

Read time: 3 min

Congress highlights

Real world study casts new light on potential of polypharmacy

The fact that 20-25% of patients with schizophrenia are treated with more than one antipsychotic1...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country